UNIGE document Scientific Article
previous document  unige:55533  next document
add to browser collection

Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease

Lamireau, Thierry
Cézard, Jean-Pierre
Dabadie, Alain
Goulet, Olivier
Lachaux, Alain
Turck, Dominique
Maurage, Chantal
Morali, Alain
show hidden authors show all authors [1 - 19]
Published in Inflammatory Bowel Diseases. 2004, vol. 10, no. 6, p. 745-50
Abstract Infliximab, a monoclonal antibody against tumor necrosis factor-alpha, has been shown to be effective for the treatment of refractory Crohn's disease in adult patients, but experience in pediatrics is limited. This retrospective study included 88 children and adolescents, 39 girls and 49 boys, with a median age of 14 years (range 3.3-17.9). Infliximab was indicated for active disease (66%) and/or fistulas (42%) that were refractory to corticosteroids (70%), and/or other immunosuppressive (82%) agents, and/or parenteral nutrition (20%). Patients received 1 to 17 infusions (median 4) of 5 mg/kg (range 3.8-7.3) of infliximab during a median time period of 4 months (1-17 months). Infusion reaction was noted in 13 patients (15%), with a total of 16 reactions in 450 infusions (4%). At Day 90 after the first infusion of infliximab, symptoms improved in 49% of patients, whereas 29% of patients were in remission and 13% of patients relapsed. From Day 0 to Day 90, Harvey-Bradshaw score decreased from 7.5 to 2.8 (P < 0.001), C-reactive protein from 36 to 16 mg/L (P < 0.01), and 1-hour erythrocyte sedimentation rate from 35 to 17 mm (P < 0.01). Dosage of corticosteroids decreased from to 0.59 to 0.17 mg/kg/d (P < 0.001); 53% of patients could be weaned of corticosteroids and 92% of parenteral nutrition. Treatment with infliximab is well tolerated and effective in most children and adolescents with Crohn's disease that is refractory to conventional immunosuppressive therapy. Nevertheless, long-term efficacy remains to be shown, and further studies are urgently needed to precisely determine the best modality of continuing treatment.
Keywords AdolescentAntibodies, Monoclonal/administration & dosage/adverse effects/therapeutic useChildChild, PreschoolCrohn Disease/drug therapy/pathologyEuropeFemaleGastrointestinal Agents/administration & dosage/adverse effects/therapeutic useHumansInfantInfusions, IntravenousMaleMedical RecordsRetrospective StudiesTreatment OutcomeTumor Necrosis Factor-alpha/antagonists & inhibitors
PMID: 15626892
Full text
Article (Published version) (137 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group Gastroentérologie et transplantation (pédiatrie) (181)
(ISO format)
LAMIREAU, Thierry et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. In: Inflammatory bowel diseases, 2004, vol. 10, n° 6, p. 745-50. https://archive-ouverte.unige.ch/unige:55533

318 hits

0 download


Deposited on : 2015-04-14

Export document
Format :
Citation style :